IKT vs GILD: Which Stock is Better?

Side-by-side comparison of Inhibikase Therapeutics Inc and Gilead Sciences Inc in 2026

Comparison Updated:

IKT

Inhibikase Therapeutics Inc

$1.76

GILD

Gilead Sciences Inc

$138.67

Key Metrics Comparison

MetricIKTGILDWinner
Market Cap$225.78M$174.33BGILD
P/E RatioN/A20.72GILD
EPS (TTM)$N/A$6.78GILD
Revenue Growth-1.0%0.0%GILD
Gross Margin-3062780800.0%78.8%GILD

Analyze IKT

Full quant analysis

Analyze GILD

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is IKT or GILD a better investment?

Comparing IKT and GILD: Inhibikase Therapeutics Inc has a market cap of $225.78M while Gilead Sciences Inc has $174.33B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between IKT and GILD?

IKT (Inhibikase Therapeutics Inc) and GILD (Gilead Sciences Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: IKT or GILD?

Based on P/E ratios, compare detailed valuation metrics on our dashboard.

Which is growing faster: IKT or GILD?

GILD has higher revenue growth at 0.0% vs -1.0% for IKT.

Which company is more profitable: IKT or GILD?

Gilead Sciences Inc (GILD) has higher gross margins at 78.8% compared to -3062780800.0% for IKT.

Which is the larger company: IKT or GILD?

Gilead Sciences Inc (GILD) is larger with a market cap of $174.33B compared to $225.78M for IKT.

Should I buy IKT or GILD in 2026?

Both IKT and GILD have investment merit. IKT trades at $1.76 while GILD trades at $138.67. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between IKT and GILD stock?

Key differences: Market Cap ($225.78M vs $174.33B), P/E Ratio (N/A vs 20.7x), Revenue Growth (-1.0% vs 0.0%), Gross Margin (-3062780800.0% vs 78.8%).

Popular Stock Comparisons